GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

TREXIMET (Formerly Known as TREXIMA) for the Acute Treatment of Probable Migraine (ICHD-II 1.6.1)

Phase 3

Completed

Conditions: Migraine, Without Aura

Interventions: Drug: Placebo
Drug: sumatriptan succinate / naproxen sodium

First Posted Date: 2006-10-13

Last Posted Date: 2016-12-16

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 679

Registration Number: NCT00387881

Locations: 🇺🇸
GSK Investigational Site, Milwaukee, Wisconsin, United States

Lapatinib Versus Placebo Given Concurrently With Cisplatin And Radiotherapy In Patients With Unresected Head And Neck Cancer

Phase 2

Completed

Conditions: Neoplasms, Head and Neck

Interventions: Drug: Lapatinib oral tablets
Drug: radiotherapy
Drug: cisplatin chemotherapy

First Posted Date: 2006-10-12

Last Posted Date: 2015-06-25

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 67

Registration Number: NCT00387127

Locations: 🇬🇧
GSK Investigational Site, Sheffield, United Kingdom

Effect Of Rilapladib (SB-659032) On Platelet Aggregation

Phase 1

Completed

Conditions: Atherosclerosis
Healthy Subjects

First Posted Date: 2006-10-12

Last Posted Date: 2015-04-15

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 58

Registration Number: NCT00387257

Locations: 🇦🇺
GSK Investigational Site, Randwick, New South Wales, Australia

Study to Evaluate Reactogenicity and Immunogenicity of Revaccination With Adjuvanted Influenza Vaccine in Elderly Adults

Phase 2

Completed

Conditions: Influenza

First Posted Date: 2006-10-11

Last Posted Date: 2016-10-07

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 200

Registration Number: NCT00386698

Locations: 🇧🇪
GSK Investigational Site, Gent, Belgium

A Study To Evaluate Formulations And Food Effect On GSK364735 In Healthy Subjects.

Phase 1

Completed

Conditions: HIV Infection
Infection, Human Immunodeficiency Virus

First Posted Date: 2006-10-11

Last Posted Date: 2012-06-04

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 56

Registration Number: NCT00386347

Locations: 🇺🇸
GSK Investigational Site, Evansville, Indiana, United States

Study to Evaluate the Immunogenicity and Safety of a Second Vaccination With the Adjuvanted Influenza Vaccine Candidate

Phase 2

Completed

Conditions: Influenza

Interventions: Biological: FluarixTM
Biological: Influenza Vaccine GSK1247446A

First Posted Date: 2006-10-11

Last Posted Date: 2018-06-08

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 678

Registration Number: NCT00385840

Locations: 🇳🇴
GSK Investigational Site, Stavanger, Norway

Study to Evaluate Reactogenicity and Immunogenicity of Revaccination With Adjuvanted Influenza Vaccine in Elderly

Phase 2

Completed

Conditions: Influenza

First Posted Date: 2006-10-11

Last Posted Date: 2018-02-26

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 74

Registration Number: NCT00386113

Locations: 🇧🇪
GSK Investigational Site, Gent, Belgium

A Type 2 Diabetes Study of the Longer-Term Glycemic Effect of AVANDAMET vs. Metformin

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Metformin 500 mg (ttd)
Drug: Avandamet 6 mg/1500 mg (ttd)
Drug: Metformin 1000 mg (ttd)
Drug: Avandamet 4 mg/1000 mg (ttd)
Drug: Metformin 1500 mg (ttd)
Drug: Avandamet 2 mg/500 mg (ttd)
Drug: Metformin 2000 mg (ttd)
Drug: Avandamet 8 mg/ 2000 mg (ttd)

First Posted Date: 2006-10-11

Last Posted Date: 2016-11-23

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 688

Registration Number: NCT00386100

Locations: 🇨🇳
GSK Investigational Site, Taoyuan Hsien, Taiwan

Evaluate Protective Efficacy of Diff Strengths of Human Rotavirus Vaccine After Admn of 2 Doses to Infants Aged 2 Months

Phase 2

Completed

Conditions: Infections, Rotavirus

First Posted Date: 2006-10-09

Last Posted Date: 2019-12-27

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 2640

Registration Number: NCT00385320

Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults

Phase 3

Completed

Conditions: Acellular Pertussis
Diphtheria
Tetanus

Interventions: Biological: Fluarix®
Biological: Boostrix®

First Posted Date: 2006-10-09

Last Posted Date: 2019-06-10

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1726

Registration Number: NCT00385255

Locations: 🇺🇸
GSK Investigational Site, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy